| Status: Superseded | ||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED OCTOBER 2010. Refer to TA206: Bendamustine for the treatment of indolent (low grade) non-Hodgkin's lymphoma that is refractory to rituximab (terminated appraisal) for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
||
|
||
Medicine details |
||
| Medicine name | bendamustine (Levact®) | |
| Formulation | 2.5 mgml powder for concentrate for solution for infusion | |
| Reference number | 39 | |
| Indication | Treatment of indolent non-Hodgkin's lymphomas as monotherapy in patients who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen |
|
| Company | Napp Pharmaceuticals Ltd | |
| BNF chapter | Malignant disease & immunosuppression | |
| Submission type | Non-submission | |
| Status | Superseded | |
| Ratification by Welsh Government | 05/11/2010 | |
| Date of issue | 05/11/2010 | |
| NICE guidance | ||